(ORO-trunc) (SEQ ID NO:5); opossum CH2—mouse CH3—opossum CH4 (OMO) (SEQ ID NO:6); opossum CH2—CH3—CH4 (OOO) (SEQ ID NO:3); platypus CH2—CH3—CH4 (PPP) (SEQ ID NO:7); opossum CH2—human CH3—opossum CH4 (OHO) (SEQ ID NO:8); opossum CH2—pig CH3—opossum CH4 (OPO) (SEQ ID NO:9); and opossum CH2—dog CH3—opossum CH4 (ODO) (SEQ ID NO:10). The arrows indicate domain borders.

In the claims:

Please cancel claims 41-54 without prejudice.

Please amend claims 25, 27, 28, 33, 35, 36, and 38 as follows:

--25. (Amended Twice) An immunogenic polypeptide, consisting essentially of a self IgE CH3 domain and one or more non-self IgE domains, wherein at least one of said non-self IgE domains comprises an IgE sequence present in a non-placental mammal, wherein said immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal, and wherein said immunogenic polypeptide lacks a CH1 domain of IgE.

G3

27. (Amended Twice) The immunogenic polypeptide of claim 26, wherein the sequence of said immunogenic polypeptide is as set forth in SEQ ID NO:4.

G4

28. (Amended Once) The immunogenic polypeptide of claim 25, wherein said non-placental mammal is selected from the group consisting of opossum, platypus, koala, kangaroo, wallaby, and wombat.

33. (Amended Twice) An immunogenic polypeptide, consisting essentially of one or more non-self IgE domains, and at least an N-terminal half of a self IgE CH3 domain, wherein at least one of said non-self IgE domains comprises an IgE sequence present in a non-placental mammal, and wherein said immunogenic polypeptide is effective to induce an anti-self IgE response in a mammal.

G5

35. (Amended Twice) The immunogenic polypeptide of claim 34, wherein the sequence of said immunogenic polypeptide is as set forth in SEQ ID NO:4.

G6 36. (Amended Once) The immunogenic polypeptide of claim 33, wherein said non-placental mammal is selected from the group consisting of opossum, platypus, koala, kangaroo, wallaby, and wombat.

G7 38. (Amended Twice) The immunogenic polypeptide of claim 33, wherein one of said non-self IgE domains is an IgE CH2 domain, wherein one of said non-self IgE domains is an IgE CH4 domain, and wherein said at least an N-terminal half of a self IgE CH3 domain is located between said IgE CH2 domain and said IgE CH4 domain[--]